Pharmaceutical News

RSS

Experimental anticancer compound appears to reverse behaviors associated with schizophrenia

Johns Hopkins researchers say that an experimental anticancer compound appears to have reversed behaviors associated with schizophrenia and restored some lost brain cell function in adolescent mice with a rodent version of the devastating mental illness.

1 Apr 2014

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured.

31 Mar 2014

New study shows anti-anxiety drugs and sleeping pills associated with increased risk of death

Anti-anxiety drugs and sleeping pills have been linked to an increased risk of death, according to new research from the University of Warwick.

31 Mar 2014

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

31 Mar 2014

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727.

31 Mar 2014

Dongkook Pharmaceutical to launch Probi Mage dietary supplement in South Korea

Probi has signed a distribution agreement with Dongkook Pharmaceutical Co., Ltd., based in Seoul, South Korea for the distribution of Probi´s gut health product, Probi Mage®. The Product will be launched under Probi's brand in South Korea in the second quarter of 2014.

31 Mar 2014

Pfizer issues statement on FDA approval of non-prescription drug, Nexium 24HR

Today the U.S. Food and Drug Administration (FDA) approved over-the-counter Nexium® 24HR (esomeprazole 20mg) marking a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years.

31 Mar 2014

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group plc ('Clinigen' or the 'Group') the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The Financial terms of the acquisition are not being disclosed.

From Clinigen Group 31 Mar 2014

Otsuka acquires rights to develop and sell Eisai’s DACOGEN in the US, Canada and Japan

Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license for DACOGEN® (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd., giving Otsuka full development and commercialization rights for the product in the former Eisai territories of the United States, Canada and Japan.

31 Mar 2014

Cheap drug holds promise of treating heart attack patients

The initial results of this trial were published a few months ago (Circulation. 2013;128:1495-1503), and showed that patients who received this treatment during emergency transit to hospital had much smaller amounts of dead heart muscle than those randomly assigned to receive no treatment.

31 Mar 2014

Study on effects of cholesterol-lowering medications on sexual health

A new study is giving hope to older men who are concerned about the effects of cholesterol-lowering medications on their sexual health.

31 Mar 2014

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions.

31 Mar 2014

Popular cholesterol-lowering drugs may offer added benefit for men with erectile dysfunction

Statins are associated with a significant improvement in erectile function, a fact researchers hope will encourage men who need statins to reduce their risk of heart attack to take them, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session.

31 Mar 2014

Actavis gets favorable ruling in patent suit against generic Lialda

Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent).

29 Mar 2014

NeuroVive presents clinical data of NVP018 for treatment of chronic hepatitis B infections at EASL

NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.

29 Mar 2014

RegeneRx obtains $1.35M payment pursuant to product license, securities purchase deal with G-treeBNT

RegeneRx Biopharmaceuticals, Inc. today announced that it received the initial $1.35 million payment pursuant to its product license and securities purchase agreement with G-treeBNT Co., Ltd (formerly Digital Aria Co., Ltd.), headquartered in Gyeonggi-do, Korea, for G-treeBNT to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S.

29 Mar 2014

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Today Biogen Idec announced that the U.S. Food and Drug Administration has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body.

29 Mar 2014

Researchers develop fluorescent sensor to identify presence of drug used to spike beverages

A team of researchers from the National University of Singapore (NUS) has developed the world's first fluorescent sensor to identify the presence of a drug known as GHB that is commonly used to spike beverages. When the sensor is mixed with a sample of a beverage containing GHB, the mixture changes colour in less than 30 seconds, making detection of the drug fast and easy.

29 Mar 2014

Study highlights benefits of using multiple injections to treat Sanfilippo syndrome type III B

New insight has been gained into treating an inherited disorder that creates serious neurological and behavioral disabilities in children and usually leads to death in the teen years.

28 Mar 2014

EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.

28 Mar 2014

Pharmaceutical News

Experimental anticancer compound appears to reverse behaviors associated with schizophrenia

FDA approves additional manufacturing suite for Pacira’s EXPAREL

New study shows anti-anxiety drugs and sleeping pills associated with increased risk of death

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Dongkook Pharmaceutical to launch Probi Mage dietary supplement in South Korea

Pfizer issues statement on FDA approval of non-prescription drug, Nexium 24HR

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Otsuka acquires rights to develop and sell Eisai’s DACOGEN in the US, Canada and Japan

Cheap drug holds promise of treating heart attack patients

Study on effects of cholesterol-lowering medications on sexual health

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Popular cholesterol-lowering drugs may offer added benefit for men with erectile dysfunction

Actavis gets favorable ruling in patent suit against generic Lialda

NeuroVive presents clinical data of NVP018 for treatment of chronic hepatitis B infections at EASL

RegeneRx obtains $1.35M payment pursuant to product license, securities purchase deal with G-treeBNT

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Researchers develop fluorescent sensor to identify presence of drug used to spike beverages

Study highlights benefits of using multiple injections to treat Sanfilippo syndrome type III B

EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News